KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-cash Items (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 15 years of Non-cash Items data on record, last reported at $37.2 million in Q3 2025.

  • For Q3 2025, Non-cash Items fell 31.24% year-over-year to $37.2 million; the TTM value through Sep 2025 reached $37.2 million, down 31.24%, while the annual FY2024 figure was $10.1 million, 9989.0% up from the prior year.
  • Non-cash Items reached $37.2 million in Q3 2025 per IONS's latest filing, down from $42.3 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $101.8 million in Q1 2021 and bottomed at $100000.0 in Q4 2023.
  • Average Non-cash Items over 5 years is $48.0 million, with a median of $51.9 million recorded in 2025.
  • Peak YoY movement for Non-cash Items: tumbled 98.94% in 2023, then soared 9989.0% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $800000.0 in 2021, then soared by 1075.0% to $9.4 million in 2022, then crashed by 98.94% to $100000.0 in 2023, then skyrocketed by 9989.0% to $10.1 million in 2024, then soared by 268.72% to $37.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $37.2 million in Q3 2025, $42.3 million in Q2 2025, and $51.9 million in Q1 2025.